Status:
UNKNOWN
Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?
Lead Sponsor:
Maastricht University
Collaborating Sponsors:
Zuyderland Medisch Centrum
Maastricht University Medical Center
Conditions:
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
Ki-67 is used as a marker for determination of the proliferative activity in solid tumors. The use within hemato-oncological malignancies is limited. This is related to limited technical possibilities...
Eligibility Criteria
Inclusion
- MDS and AML patients
Exclusion
- Ongoing radio- and/or chemotherapy
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04517175
Start Date
September 1 2020
End Date
September 1 2025
Last Update
August 18 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.